Compare Kraft Heinz Co (KHC) vs Pfizer Inc (PFE) Price & Performance

Kraft Heinz (KHC) trades at $26.05, up 0.66% today, with a bullish technical signal and recent earnings beats. The stock shows strong operating cash flow of $4.46B in 2025 but faces profitability challenges with a net income margin of -23.05%. Analysts are mixed, with 57% holding a neutral stance, while the company's reorganization aims to spur growth. The dividend yield remains attractive at approximately 6.4%, supported by solid cash generation.

Outlook: KHC offers value with a low P/B of 0.73 and high dividend, but risks include persistent net losses and high debt. The upcoming Q2 2026 earnings on August 5 will be critical for confirming turnaround progress. Investors should weigh the dividend stability against fundamental weaknesses in a competitive food sector.

Pfizer (PFE) trades at $25.05, down 0.36% on the day, with a bullish technical signal supported by strong quarterly earnings beats. The company maintains solid profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated post-pandemic. Recent news highlights pipeline advancements in oncology and obesity treatments, positioning PFE for potential growth catalysts in 2026.

The outlook for Pfizer is cautiously optimistic, with a consensus price target of $28.25 offering 13% upside. Key opportunities include dividend stability and pipeline innovation, while risks involve patent cliffs and competitive pressures. Analyst sentiment is mixed with 38% buy ratings, reflecting balanced views on recovery potential versus near-term challenges.